Mundipharma to commercialize Samsung Bioepis to biosimilars Into Hong Kong and Taiwan

17 January 2020

Mundipharma today announced a partnership with South Korea’s Samsung Bioepis to commercialize the latter’s first-wave biosimilar candidates in Taiwan and Hong Kong.

The partnership covers Samsung Bioepis’ biosimilar candidates in the field of immunology and oncology, including SB5 (adalimumab), AbbVie’s (NYSE: ABBV) Humira, SB4 (etanercept), and Amgen’s (Nasdaq: AMGN) Enbrel, as well as SB3 (trastuzumab), Roche’s (ROG: SIX) Herceptin, and SB8 (bevacizumab), the Swiss pharma major’s Avastin.

Through the partnership, Mundipharma will be the exclusive commercialization partner, while Samsung Bioepis will remain the Marketing Authorization Holder (MAH), responsible for clinical development, regulatory registration, and manufacture of the biosimilars.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK